Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N.

Br J Haematol. 2011 Nov;155(4):457-67. doi: 10.1111/j.1365-2141.2011.08882.x. Epub 2011 Oct 20.

2.

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F, Valdez J, Boss C, Samsel L, McCoy JP Jr, Wilson WH, Pittaluga S, Wiestner A.

Haematologica. 2009 Sep;94(9):1266-73. doi: 10.3324/haematol.2009.005835.

3.

Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.

Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Payer AR, López-Soto A, Gonzalez S.

Biomed Res Int. 2014;2014:265840. doi: 10.1155/2014/265840. Epub 2014 Sep 17.

4.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC.

Blood. 2010 Apr 1;115(13):2619-29. doi: 10.1182/blood-2009-09-242438. Epub 2009 Nov 24.

5.

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C.

Blood. 2000 Feb 1;95(3):999-1006.

6.

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.

Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC.

Br J Haematol. 2009 Mar;144(6):848-55. doi: 10.1111/j.1365-2141.2008.07548.x. Epub 2009 Jan 12.

7.

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC.

Leuk Lymphoma. 2010 Jan;51(1):27-38. doi: 10.3109/10428190903350405. Review.

8.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC.

J Clin Oncol. 2008 May 20;26(15):2519-25. doi: 10.1200/JCO.2007.13.9709. Epub 2008 Apr 21.

9.

Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM.

Cancer. 2011 Sep 1;117(17):3999-4008. doi: 10.1002/cncr.25983. Epub 2011 Feb 24.

10.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ.

Blood. 2011 Apr 21;117(16):4323-7. doi: 10.1182/blood-2010-11-315705. Epub 2011 Mar 4.

11.

Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner.

Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A.

Br J Haematol. 2012 Apr;157(1):59-66. doi: 10.1111/j.1365-2141.2011.08984.x. Epub 2011 Dec 15.

PMID:
22171982
12.

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

Maffei R, Colaci E, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R.

Crit Rev Oncol Hematol. 2016 Jan;97:291-302. doi: 10.1016/j.critrevonc.2015.09.003. Epub 2015 Sep 30. Review.

PMID:
26454471
13.

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes.

Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M.

Blood. 2005 Mar 15;105(6):2436-42. Epub 2004 Nov 9.

14.

Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S, Miller A, Hernandez-Illatazurri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K.

Cancer. 2011 May 15;117(10):2127-35. doi: 10.1002/cncr.25748. Epub 2010 Nov 29.

15.

Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.

Romano C, De Fanis U, Sellitto A, Dalla Mora L, Chiurazzi F, Giunta R, Rotoli B, Lucivero G.

Leuk Lymphoma. 2003 Nov;44(11):1963-71.

PMID:
14738151
16.

Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Fiorcari S, Martinelli S, Bulgarelli J, Audrito V, Zucchini P, Colaci E, Potenza L, Narni F, Luppi M, Deaglio S, Marasca R, Maffei R.

Haematologica. 2015 Feb;100(2):253-62. doi: 10.3324/haematol.2014.113217. Epub 2014 Nov 14.

17.

Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia.

Rezvany MR, Jeddi-Tehrani M, Rabbani H, Lewin N, Avila-Cariño J, Osterborg A, Wigzell H, Mellstedt H.

Br J Haematol. 2000 Nov;111(2):608-17.

PMID:
11122109
18.

Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.

Schulz A, Dürr C, Zenz T, Döhner H, Stilgenbauer S, Lichter P, Seiffert M.

Blood. 2013 Mar 28;121(13):2503-11. doi: 10.1182/blood-2012-08-447664. Epub 2013 Jan 24.

19.
20.

Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern.

Rezvany MR, Jeddi-Tehrani M, Biberfeld P, Söderlund J, Mellstedt H, Osterborg A, Rabbani H.

Br J Haematol. 2001 Nov;115(2):263-71.

PMID:
11703320

Supplemental Content

Support Center